A large-scale study involving more than 120,000 older adults has found that commonly prescribed osteoporosis drugs may be associated with a significantly reduced risk of Alzheimer’s disease and other forms of dementia, with researchers reporting a risk reduction of up to 24 percent among users of the medications. The findings, published in a leading scientific journal, draw on years of patient data and represent one of the most substantial investigations to date into a possible link between bone-strengthening treatments and cognitive health. Osteoporosis medications, known as bisphosphonates, are among the most widely prescribed drugs for older populations worldwide.
The research stopped short of establishing a causal relationship, and the authors cautioned that the observational design means residual confounding factors cannot be ruled out. Independent experts described the results as intriguing but preliminary, noting that randomized controlled trials would be needed before any clinical recommendations could be made. Nevertheless, the study raises the prospect that existing, well-characterized medications could offer a dual benefit for aging populations, addressing bone loss while potentially shielding the brain. Further research is expected to examine the biological mechanisms that might underlie the association and to determine whether specific drugs or patient groups stand to benefit most.
Independent reporting synthesized from primary wires and global correspondents.